Efficacy and safety of pembrolizumab and docetaxel in patients with aggressive radioactive iodine refractory thyroid cancer or salivary gland cancer

Trial Profile

Efficacy and safety of pembrolizumab and docetaxel in patients with aggressive radioactive iodine refractory thyroid cancer or salivary gland cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel
  • Indications Salivary gland cancer; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms iPRIME
  • Most Recent Events

    • 05 Jul 2017 New trial record
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top